Cargando…

PR3-ANCAs predict relapses in ANCA-associated vasculitis patients after rituximab

Background. The primary challenge of anti-neutrophil cytoplasmic antibody (ANCA)-associated vasculitis (AAV) patient care is the early detection of relapses to prevent organ damage and increase survival. Potential biomarkers for relapses are ANCA and B cells, but their predictive value is a matter o...

Descripción completa

Detalles Bibliográficos
Autores principales:	van Dam, Laura S, Dirikgil, Ebru, Bredewold, Edwin W, Ray, Argho, Bakker, Jaap A, van Kooten, Cees, Rabelink, Ton J, Teng, Yoe K Onno
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Oxford University Press 2020
Materias:	Original Articles
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8311572/ https://www.ncbi.nlm.nih.gov/pubmed/32601673 http://dx.doi.org/10.1093/ndt/gfaa066

Ejemplares similares

ExploriNg DUrable Remission with Rituximab in ANCA-associatEd vasculitis (ENDURRANCE trial): protocol for a randomised controlled trial
por: Dirikgil, Ebru, et al.
Publicado: (2022)

Identifying relevant determinants of in-hospital time to diagnosis for ANCA-associated vasculitis patients
por: Dirikgil, Ebru, et al.
Publicado: (2022)

The impact of reclassification by the 2022 ACR/EULAR classification criteria on risk factors for relapse in patients with ANCA-associated vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023)

Rituximab as therapy to induce remission after relapse in ANCA-associated vasculitis
por: Smith, Rona M, et al.
Publicado: (2020)

Preliminary Assessment of Safety and Tolerability of Avacopan During the Early Access Program for ANCA-Associated Vasculitis
por: van Leeuwen, Jolijn R, et al.
Publicado: (2023)

Specific IgG glycosylation differences precede relapse in PR3-ANCA associated vasculitis patients with and without ANCA rise
por: Wojcik, Iwona, et al.
Publicado: (2023)

Long-term maintenance rituximab for ANCA-associated vasculitis: relapse and infection prediction models
por: McClure, Mark E, et al.
Publicado: (2020)

Co-trimoxazole and prevention of relapses of PR3-ANCA positive vasculitis with pulmonary involvement
por: Zycinska, K, et al.
Publicado: (2009)

PReS-FINAL-2311: Rituximab in paediatric ANCA-associated vasculitis
por: Mestrallet, G, et al.
Publicado: (2013)

Combination Therapy With Rituximab and Cyclophosphamide for Remission Induction in ANCA Vasculitis
por: Cortazar, Frank B., et al.
Publicado: (2017)

Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results
por: Kraaij, Tineke, et al.
Publicado: (2020)

Diagnosing ANCA-associated vasculitis in ANCA positive patients: A retrospective analysis on the role of clinical symptoms and the ANCA titre
por: Houben, Eline, et al.
Publicado: (2016)

Membrane expression of neutrophil proteinase 3 (PR3) is associated with relapse in PR3-ANCA related vasculitis
por: Rarok, AA, et al.
Publicado: (2002)

Rhinologic and sinonasal changes in PR3 ANCA pulmonary vasculitis
por: Zycinska, K, et al.
Publicado: (2010)

Pathophysiology of ANCA-Associated Small Vessel Vasculitis
por: Kallenberg, Cees G. M.
Publicado: (2010)

Galactosylation and Sialylation Levels of IgG Predict Relapse in Patients With PR3-ANCA Associated Vasculitis
por: Kemna, Michael J., et al.
Publicado: (2017)

Highly Sensitive Flow Cytometric Detection of Residual B-Cells After Rituximab in Anti-Neutrophil Cytoplasmic Antibodies-Associated Vasculitis Patients
por: van Dam, Laura S., et al.
Publicado: (2020)

ANCA associated vasculitis
por: Hunter, Robert W, et al.
Publicado: (2020)

Reactivity against Complementary Proteinase-3 Is Not Increased in Patients with PR3-ANCA-Associated Vasculitis
por: Tadema, Henko, et al.
Publicado: (2011)

The Efficacy and Safety of Rituximab in ANCA-Associated Vasculitis: A Systematic Review
por: Habibi, Mohammad Amin, et al.
Publicado: (2022)

Rituximab-associated hypogammaglobulinemia in ANCA-associated vasculitis: Incidence and time course
por: Tariq, Anam, et al.
Publicado: (2022)

Personalized Medicine in ANCA-Associated Vasculitis ANCA Specificity as the Guide?
por: Wallace, Zachary S., et al.
Publicado: (2019)

Clinical implications of serum thrombomodulin in PR3-ANCA-associated vasculitis
por: Zycinska, K, et al.
Publicado: (2009)

Acute PR3-ANCA vasculitis in an asymptomatic COVID-19 teenager
por: Wintler, Taylor, et al.
Publicado: (2021)

Rituximab used for simultaneous treatment of PR3‐ANCA positive vasculitis associated with rheumatoid arthritis: A case report
por: Yamada, Akihiro, et al.
Publicado: (2020)

A randomised study of rituximab and belimumab sequential therapy in PR3 ANCA-associated vasculitis (COMBIVAS): design of the study protocol
por: McClure, Mark E., et al.
Publicado: (2023)

Relapse in Anti-Neutrophil Cytoplasm Antibody (ANCA)–Associated Vasculitis
por: Salama, Alan D.
Publicado: (2019)

The immunopathology of ANCA-associated vasculitis
por: McKinney, Eoin F., et al.
Publicado: (2014)

Immunopathogenesis of ANCA-Associated Vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-associated vasculitis of the appendix
por: Leaver, Phillip J, et al.
Publicado: (2019)

Comorbidities in ANCA-associated vasculitis
por: Kronbichler, Andreas, et al.
Publicado: (2020)

ANCA-Associated Vasculitis: An Update
por: Almaani, Salem, et al.
Publicado: (2021)

Rituximab in relapsing and de novo MPO ANCA-associated vasculitis with severe renal involvement: a case series
por: Caroti, L., et al.
Publicado: (2019)

A Case of Rituximab Use as an Induction and Maintenance of Remission in ANCA-Associated Vasculitis
por: Awad, Neveen, et al.
Publicado: (2016)

Rituximab Induction and Maintenance in ANCA-Associated Vasculitis: State of the Art and Future Perspectives
por: Treppo, Elena, et al.
Publicado: (2021)

Membranous Nephropathy with Proteinase 3-ANCA-associated Vasculitis Successfully Treated with Rituximab
por: Yoshida, Shun, et al.
Publicado: (2020)

COVID-19 and ANCA-associated vasculitis: recommendations for vaccine preparedness and the use of rituximab
por: Bruchfeld, Annette, et al.
Publicado: (2021)

Infection is associated with increased risk of MPO- but not PR3-ANCA-associated vasculitis
por: Rathmann, Jens, et al.
Publicado: (2022)

The association between ambient UVB dose and ANCA-associated vasculitis relapse and onset
por: Scott, Jennifer, et al.
Publicado: (2022)

Delta Neutrophil Index Is Associated with Vasculitis Activity and Risk of Relapse in ANCA-Associated Vasculitis
por: Yoo, Juyoung, et al.
Publicado: (2018)

Cannot write session to /tmp/vufind_sessions/sess_u4tvnnojlegs0d7pg1drtdaegf